Olema Pharmaceuticals, Inc.
NASDAQ:OLMA
12.07 (USD) • At close October 21, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Olema Pharmaceuticals, Inc. |
Symbool | OLMA |
Munteenheid | USD |
Prijs | 12.07 |
Beurswaarde | 691,205,448 |
Dividendpercentage | 0% |
52-weken bereik | 8.51 - 17.791 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Sean P. Bohen M.D., Ph.D. |
Website | https://www.olema.com |
An error occurred while fetching data.
Over Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)